Silent Crohn’s disease may have little or no symptoms. It's important to monitor disease activity and treat the condition to ...
The FDA has approved Tremfya (guselkumab) for the treatment of adults with moderately to severely active Crohn disease.
Patients with moderate to severe Crohn’s disease who did not achieve clinical response to IV induction with Skyrizi ...
The FDA has approved Tremfya as the “first and only” interleukin-23 inhibitor that offers both IV and fully subcutaneous ...
The U.S. Food and Drug Administration has approved Johnson & Johnson's Tremfya (guselkumab) for adult patients with ...
Pharmaceutical Technology on MSN7d
FDA approves Johnson & Johnson’s Tremfya to treat Crohn’s diseaseJ&J has received US FDA approval for Tremfya (guselkumab), to treat moderately to severely active Crohn's disease (CD) in ...
Crohn's disease belongs to a group of conditions known as inflammatory bowel diseases (IBD). This chronic condition causes ...
Guselkumab is the first and only interleukin-23 inhibitor that offers both subcutaneous and intravenous induction options for ...
Sportschosun on MSN1d
A drop of blood distinguishes Crohn's disease from ulcerative colitis...Laying the foundation for customized treatment of inflammatory bowel diseaseInflammatory bowel disease (IBD) is expected to be more accurate and personalized. Recently, Professor Lee Hong-seop's team ...
Recommendation based on the findings from the Phase 3 studies (GALAXI programme and GRAVITI) in Crohn's disease 1,2< ...
Missing piece in Crohn’s disease is discovered—immune cells that vanish before symptoms even start! This groundbreaking ...
Treating Newly-Diagnosed Crohn's Patients With Advanced Therapy Leads to Dramatic Improvements in Outcomes Feb. 22, 2024 — A large-scale clinical trial of treatment strategies for Crohn's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback